Description: This meeting session presented a discussion on the effect of new federal policies as of 1982 on medical insurance. Topics include cost shifting, employers contributions, rebates, vouchers, and provider negotiation. From Record of the Society of Actuaries Vol. 8, No. 2

Description: Panelists discuss the future of prospective payment in Medicare, sequels to the Omnibus Budget Reconciliation Act, the Deficit Reduction Act, COBRA, fallout from the administration's Catastrophic Illness Study, and the evolution of the voucher proposal. From the 1987 Record of Society of Actuaries, Vol. 13, No. 1.

Description: This presentation from Session 61PD of the SOA 1996 Orlando Annual Meeting provides an update on changes to the Medicare health program over the last couple years. In addition, the panelists discuss the merits of additional proposed changes from the White House and both sides of the aisle in Congress. From the Record of the Society of Actuaries, Vol. 22, No. 3.

Description: Discussion of recent developments in the taxation of noncoordinated benefits such as fixed indemnity, hospital indemnity, and specified disease insurance policies. Developments include a recent Chief Counsel Advice Memorandum and proposed triagency rulemaking that would impact non coordinated benefits.

Description: Teaching session on the working Medicare contracts: background on the origin of Medicare risk contracts, feasibility of an HMO or competitive medical plan entering the Medicare risk market, and outline of the HCFA adjusted community rate filing process.

Description: At this presentation from Session 72D of the SOA 1996 Colorado Springs Meeting, the panelists debate legislative changes to the Medicare program. Included is an overview of the changes in the 1995 legislation, expected savings in the Federal budget, a debate as to the realism of these expected savings, reaction of enrollees, and a discussion of anticipated effects on the private sector of the healthcare system. From the Record of the Society of Actuaries, Vol. 22, No. 2.

Description: An article recapping the SOA's participation in the NAIC Summer 2023 meeting.

Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.

Description: Corin Chapman explores the many perspectives to consider when determining appropriate insurance regulation.

Description: Savings from biosimilars have accelerated significantly in the past few years. There has been a number of relatively recent biosimilar launches that can help to shape our expectations of the financial impact that could result from this year’s big event. Savings from biosimilars have accelerated significantly in the past few years. There has been a number of relatively recent biosimilar launches that can help to shape our expectations of the financial impact that could result from this year’s big event.